On July 2, WuXi XDC rose 3.16% in regular trading, trading at HK$58.9/share, with turnover of HK$196 million. The rally was primarily driven by continued strength across the CXO sector and the company's ongoing capital return initiatives.

The broader CXO sector exhibited notable sector-wide momentum, with peers GenScript Biotech up 5.15%, WuXi Biologics up 2.89%, and XtalPi up 1.96%. Bocom International recently highlighted WuXi XDC as a top pick among high-growth CDMO players with superior investment value. Guotai Junan Securities maintains an Overweight rating with a target price of HK$84.38, citing the company's enhanced earnings visibility.

On the capital side, the company previously announced a share buyback plan of up to US$100 million funded by internal resources, and shareholders authorized repurchases of up to 10% of issued shares. WuXi XDC's backlog stood at approximately US$1.489 billion as of year-end, representing 50.3% year-over-year growth, underpinning strong forward revenue visibility.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)